Navigation Links
Galectin Therapeutics Reports Full Year and Fourth Quarter 2012 Financial Results
Date:3/29/2013

ss applicable to common stock of $2.7 million, or ($0.17) per share, basic and diluted, compared with a net loss of $3.7 million or ($0.29) per share for the same period in 2011. For the full year 2012, the Company reported a net loss applicable to common stock of $10.9 million, or ($0.72) per share, basic and diluted, compared with a net loss of $12.7 million, or $(1.06) per share in 2011. The full year 2012 results include $0.2 million of other income as well as $1.2 million of non-cash expense related to dividends and accretion on the preferred stock compared with $1.8 million in 2011. The weighted average number of shares used to calculate loss per share increased for the 2012 periods compared to the 2011 periods due primarily to the March 2012 offering of 2.7 million common shares as well as the payment of dividends in common stock.

Research and development expense for the fourth quarter of 2012 was $1.0 million, compared with $0.9 million for the same period in 2011. Research and development expense for the full year 2012, was $4.5 million, compared with $3.6 million in 2011. The increase for the fourth quarter and the year-over-year expenses is due primarily to increased pre-clinical activity in our fibrosis program as we prepared to file an IND in January 2013 and begin a Phase I clinical trial, offset by decreased expenses related to stock-based compensation.General and administrative expense for the fourth quarter of 2012 was $1.4 million, compared with $2.5 million for the same period in 2011. General and administrative expense for the full year 2012 was $5.4 million as compared to $6.9 million for 2011. The decrease for the fourth quarter and full year 2012 is due primarily to the recognition of a $1.0 million payment related to a separation agreement during the fourth quarter of 2011. Additionally, the decrease in expense for the fourth quarter and full year 2012 is due primarily to overall decreased business development costs as we decreased wor
'/>"/>

SOURCE Galectin Therapeutics Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Galectin-3 Assessed as a Biomarker of Heart Failure: Key Clinical Trial Findings Published by Dove Medical Press
2. Cell Therapeutics, Inc. Reports Results of Annual Meeting of Shareholders
3. Nile Therapeutics Reports 2011 Third Quarter Financial Results
4. Nile Therapeutics Announces Top-Line Results in Clinical Trial Evaluating the Subcutaneous Infusion of Cenderitide, Meets Primary Endpoint
5. Fate Therapeutics Strengthens Its iPSC Platform
6. Amsterdam Molecular Therapeutics Provides Business Update for the Third Quarter 2011
7. MarketsandMarkets: Global Prostate Cancer Therapeutics Market worth $6,457 Million by 2020
8. MarketsandMarkets: Leukemia Therapeutics Market Worth $11.3 Billion by 2020
9. Roche Signs Agreement with PTC Therapeutics to Advance Treatment for Spinal Muscular Atrophy (SMA)
10. Echo Therapeutics Announces Positive Results of Clinical Trial of its Symphony® Transdermal Continuous Glucose Monitoring (tCGM) System in Patients With Type 1 and Type 2 Diabetes
11. Aratana Therapeutics Completes $15 Million Series B Financing
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/3/2015)... ... August 03, 2015 , ... Sterlitech Corporation ... its comprehensive line of analytical laboratory equipment. With optimized features, such as PTFE-coated ... a chemically resistant and maintenance-free solution for a broad range of vacuum filtration ...
(Date:7/31/2015)... ... 2015 , ... Global Resorcinol Market 2015-2019 is a comprehensive ... global resorcinol industry. The report highlights the various growth prospects and the prevalent ... of primary and secondary inputs from the existing players of the resorcinol market. ...
(Date:7/31/2015)... ... July 31, 2015 , ... R-Biopharm is proud ... partially hydrolyzed gluten in foods, has been accepted by AOAC International as Official ... Gluten in Fermented Cereal-Based Products by R5 Competitive ELISA,” based on a specific ...
(Date:7/30/2015)... AACC welcomed thousands of medical professionals ... Meeting & Clinical Lab Expo in ... showcased revolutionary advancements in clinical testing technology and ... to diagnose patients quickly and accurately and make ... As of Wednesday, July 29, more than ...
Breaking Biology Technology:Sterlitech Launches New Line of Vacuum Pumps 2Resorcinol Market to Grow at 6% CAGR to 2019 Says New Research Report at ReportsnReports.com 2Resorcinol Market to Grow at 6% CAGR to 2019 Says New Research Report at ReportsnReports.com 3Resorcinol Market to Grow at 6% CAGR to 2019 Says New Research Report at ReportsnReports.com 4RIDASCREEN® Competitve Gliadin Receives AOAC Official First Action Status 2Innovative Research on Cancer, Heart Disease, and Infectious Diseases Draws More than 17,500 Attendees to 2015 AACC Annual Meeting 2Innovative Research on Cancer, Heart Disease, and Infectious Diseases Draws More than 17,500 Attendees to 2015 AACC Annual Meeting 3Innovative Research on Cancer, Heart Disease, and Infectious Diseases Draws More than 17,500 Attendees to 2015 AACC Annual Meeting 4
... BAX ), will host a quarterly conference call to ... 16, 2009, at 8:30 a.m. Eastern Time (7:30 a.m. Central ... or 703-639-1156 (international). Please dial into the call at ... for the operator to connect you.This call is being webcast ...
... /PRNewswire-FirstCall/ - Vasogen Inc. (NASDAQ: VSGN ; TSX:VAS) today ... February 28, 2009. All dollar amounts referenced herein are in ... our cash and cash equivalents totaled $7.3 million, compared with ... net loss for the three months ended February 28, 2009 ...
... National Healthcare Decisions Day, your choice in times of ... Inc .( www.usoncology.com ), supporting the ... providers, payers and manufacturers to advance cancer care in ... National Healthcare Decisions Day ( ...
Cached Biology Technology:Vasogen Announces First Quarter 2009 Results 2Vasogen Announces First Quarter 2009 Results 3Vasogen Announces First Quarter 2009 Results 4Vasogen Announces First Quarter 2009 Results 5Vasogen Announces First Quarter 2009 Results 6Vasogen Announces First Quarter 2009 Results 7Vasogen Announces First Quarter 2009 Results 8Vasogen Announces First Quarter 2009 Results 9US Oncology Encourages Your Right to Decide 2US Oncology Encourages Your Right to Decide 3
(Date:7/7/2015)... , June 30, 2015 ... has announced the addition of the "Capacitive ... offering. To this date, fingerprint sensing ... technology and fingerprint sensors are well developed. This ... sensing technology. The domain of capacitive ...
(Date:7/2/2015)... , June 25, 2015 ... the addition of the "Natural Language Processing ... (Recognition, IVR, OCR, Pattern & Image Recognition) - ... offering. The key vendors occupying the ... IBM Corporation, Microsoft Corporation, NetBase Solutions, SAS Institute ...
(Date:6/30/2015)... 30, 2015 To bolster its efforts and commitment ... announced today the addition of two new team members. ... advisor and David Raviv will act as head ... Corp.,s commitment to providing the most secure solutions for the ... co-founded Layer 7 Technologies, a provider of security and management ...
Breaking Biology News(10 mins):Worldwide Capacitive Fingerprint Sensors Patent Landscape Market Report 2015-2020 - Main IP Holders include Seiko Epson, AuthenTec, Sony and STMicroelectronics 2Natural Language Processing Market by Type (Rule-Based, Statistical, and Hybrid), Technologies (Recognition, IVR, OCR, Pattern & Image Recognition) - Worldwide Forecast to 2020 2HYPR Corp. Expands Biometric Authentication Team with Enterprise All Stars 2HYPR Corp. Expands Biometric Authentication Team with Enterprise All Stars 3
... a fledgling industry, now accounts for 50 percent of the ... international team of researchers. And while the industry is more ... on marine resources by consuming large amounts of feed made ... Their findings are published in the Sept. 7 online edition ...
... University,s department of plant pathology is receiving two honors ... pathology, has been named a Fellow of the American ... distinguished contributions to plant pathology or the society. It ... the society,s membership in any one year. The ...
... Monash University biochemists, has discovered evidence at the molecular ... of Darwin,s theory of evolution. Monash University,s ... Australian Research Council and published recently in the prestigious ... general understanding of the evolution of the "machinery" of ...
Cached Biology News:Half of the fish consumed globally is now raised on farms, study finds 2Half of the fish consumed globally is now raised on farms, study finds 3K-State's plant pathology head named fellow of Phytopathology Society 2Evolution still scientifically stable 2
... ScriptCap™ m7G Capping system ... and all of the components ... 0 on the end of ... These kits feature high efficiency ...
... Detergent Removal , , ... no cross-reactivity with other proteins , Simple, ... Economical new surface technology, not based ... interfere with protein analysis. SurfactAway offers a ...
SDS-OutT SDS Precipitation Reagent...
... for fully automated systems for a broad ... configured for applications ranging from compound logistics, ... loop screening, which means it has fully ... picking and follow up studies all at ...
Biology Products: